🔎 Trials Near Me

Home › Urothelial (Transitional Cell) Carcinoma › Michigan

Urothelial (Transitional Cell) Carcinoma clinical trials in Michigan

15 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in Michigan.

Cities in Michigan

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

  • South Texas Accelerated Research Therapeutics (START), Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  • Exelixis Clinical Site #65, Detroit
  • Exelixis Clinical Site #13, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
  • and 4 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06524544

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health Medical Center - Brighton, Brighton
  • and 32 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT03866382

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

  • University of Michigan, Ann Arbor
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05874921

DBC-664 in Adult Patients With Solid Tumors

  • START Midwest, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07705035

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  • Karmanos Cancer Institute, Detroit
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07218380

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • Karmanos Cancer Institiute, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

  • University of Michigan, Ann Arbor
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06966024

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • Henry Ford Cancer Institute, Detroit
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 29, 2026 · NCT04198766

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

  • The Cancer & Hematology Centers, Big Rapids
  • Karmanos Cancer Institute, Detroit
  • Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
  • and 7 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT04879329

Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer

  • University of Michigan Comprehensive Cancer Center, Ann Arbor
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT06356155

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

  • START Midwest, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Dec 11, 2025 · NCT06943521

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Ann Arbor
  • Massive Bio SYNERGY-AI site, Lansing
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.